Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-11

IDEXX Laboratories (IDXX)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$14,580,122
Jonathan Mazelsky total, FY2025
50th
CEO pay percentile vs peers
218:1
CEO-to-median pay ratio
94.22%
Say-on-pay support, latest vote
Companies that benchmark against IDXX
21 companies name IDXX as a compensation peer

Each company listed discloses IDXX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named IDXX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Jonathan Mazelsky$1,150,000$0$5,399,881$5,400,001$2,593,000$0$37,240$14,580,122
President and Chief Executive Officer
Michael Lane594,05401,349,8551,349,949627,270098,2884,019,416
Executive Vice President and General Manager, CAG Diagnostics Business Unit
Tina Hunt594,05401,349,8551,349,949627,270024,1653,945,293
Executive Vice President, Global Strategy and Commercial
Martin Smith594,05401,349,8551,349,949627,270023,4063,944,534
Executive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security
Andrew Emerson531,1460949,864949,941577,500024,6203,033,071
Executive Vice President, Chief Financial Officer and Treasurer
Brian McKeon293,4040000058,276351,680
Former Executive Vice President, Chief Financial Officer and Treasurer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Jonathan Mazelsky$14,580,122
Michael Lane4,019,416
Tina Hunt3,945,293
Martin Smith3,944,534
Andrew Emerson3,033,071
Brian McKeon351,680

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Joseph L. (Jay) HooleyDirector2026-04-30A43$561$24,114Deferred share awardForm 4 ↗
Joseph L. (Jay) HooleyDirector2026-05-07A15800CommonForm 4 ↗
M. Anne SzostakDirector2026-05-07D257Derivative, Class A CommonForm 4 ↗
Karen PeacockDirector2026-05-07D101Derivative, Class A CommonForm 4 ↗
Lawrence D. KingsleyDirector2026-05-07D82Derivative, Class A CommonForm 4 ↗
Daniel M. JuniusDirector2026-05-07D257Derivative, Class A CommonForm 4 ↗
Joseph L. (Jay) HooleyDirector2026-05-07D158Derivative, Class A CommonForm 4 ↗
Lawrence D. KingsleyDirector2026-05-07D257Derivative, Class A CommonForm 4 ↗
Sophie V. Vandebroek, PhDDirector2026-05-07A25700CommonForm 4 ↗
Sophie V. Vandebroek, PhDDirector2026-05-07D257Derivative, Class A CommonForm 4 ↗
Karen PeacockDirector2026-05-07A10100CommonForm 4 ↗
Lawrence D. KingsleyDirector2026-05-07A25700CommonForm 4 ↗
Daniel M. JuniusDirector2026-05-07A25700CommonForm 4 ↗
Lawrence D. KingsleyDirector2026-05-07A8200CommonForm 4 ↗
M. Anne SzostakDirector2026-05-07A25700CommonForm 4 ↗
Dividend-equivalent accruals2026-05-127,0749 insiders, 20 accrual rows
George FennellExecutive Vice President2026-06-01D639Derivative, Class A CommonForm 4 ↗
George FennellExecutive Vice President2026-06-01A63900CommonForm 4 ↗
George FennellExecutive Vice President2026-06-01D284567160,968CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 38 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Joseph L. (Jay) HooleyDirector2026-04-30A43$561$24,114Deferred share awardForm 4 ↗
Joseph L. (Jay) HooleyDirector2026-05-07A15800CommonForm 4 ↗
M. Anne SzostakDirector2026-05-07D257Derivative, Class A CommonForm 4 ↗
Karen PeacockDirector2026-05-07D101Derivative, Class A CommonForm 4 ↗
Lawrence D. KingsleyDirector2026-05-07D82Derivative, Class A CommonForm 4 ↗
Daniel M. JuniusDirector2026-05-07D257Derivative, Class A CommonForm 4 ↗
Joseph L. (Jay) HooleyDirector2026-05-07D158Derivative, Class A CommonForm 4 ↗
Lawrence D. KingsleyDirector2026-05-07D257Derivative, Class A CommonForm 4 ↗
Sophie V. Vandebroek, PhDDirector2026-05-07A25700CommonForm 4 ↗
Sophie V. Vandebroek, PhDDirector2026-05-07D257Derivative, Class A CommonForm 4 ↗
Karen PeacockDirector2026-05-07A10100CommonForm 4 ↗
Lawrence D. KingsleyDirector2026-05-07A25700CommonForm 4 ↗
Daniel M. JuniusDirector2026-05-07A25700CommonForm 4 ↗
Lawrence D. KingsleyDirector2026-05-07A8200CommonForm 4 ↗
M. Anne SzostakDirector2026-05-07A25700CommonForm 4 ↗
Stuart M. Essig, PhDDirector2026-05-12A23400Derivative, Class A CommonForm 4 ↗
Joseph L. (Jay) HooleyDirector2026-05-12A23400Derivative, Class A CommonForm 4 ↗
Stuart M. Essig, PhDDirector2026-05-12A52500Derivative, Class A CommonForm 4 ↗
Bruce L. ClaflinDirector2026-05-12A52500Derivative, Class A CommonForm 4 ↗
Sam SamadDirector2026-05-12A23400Derivative, Class A CommonForm 4 ↗
Sam SamadDirector2026-05-12A52500Derivative, Class A CommonForm 4 ↗
Sophie V. Vandebroek, PhDDirector2026-05-12A52500Derivative, Class A CommonForm 4 ↗
Sophie V. Vandebroek, PhDDirector2026-05-12A23400Derivative, Class A CommonForm 4 ↗
Karen PeacockDirector2026-05-12A23400Derivative, Class A CommonForm 4 ↗
Lawrence D. KingsleyDirector2026-05-12A52500Derivative, Class A CommonForm 4 ↗
Daniel M. JuniusDirector2026-05-12A23400Derivative, Class A CommonForm 4 ↗
Karen PeacockDirector2026-05-12A52500Derivative, Class A CommonForm 4 ↗
Lawrence D. KingsleyDirector2026-05-12A16800Derivative, Class A CommonForm 4 ↗
Lawrence D. KingsleyDirector2026-05-12A23400Derivative, Class A CommonForm 4 ↗
Lawrence D. KingsleyDirector2026-05-12A7500Derivative, Class A CommonForm 4 ↗
Daniel M. JuniusDirector2026-05-12A52500Derivative, Class A CommonForm 4 ↗
Bruce L. ClaflinDirector2026-05-12A23400Derivative, Class A CommonForm 4 ↗
Irene Chang BrittDirector2026-05-12A52500Derivative, Class A CommonForm 4 ↗
Irene Chang BrittDirector2026-05-12A23400Derivative, Class A CommonForm 4 ↗
Joseph L. (Jay) HooleyDirector2026-05-12A52500Derivative, Class A CommonForm 4 ↗
George FennellExecutive Vice President2026-06-01D639Derivative, Class A CommonForm 4 ↗
George FennellExecutive Vice President2026-06-01A63900CommonForm 4 ↗
George FennellExecutive Vice President2026-06-01D284567160,968CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Martin SmithRSU2025-02-136,5376,537$1,349,949
Martin SmithRSU2025-02-131,4681,468674,928
Jonathan MazelskyPSU2025-02-132,34911,74523,4905,399,881
Jonathan MazelskyPSU2025-02-134,6005,400,001
Tina HuntRSU2025-02-131,4681,468674,928
Tina HuntRSU2025-02-131,4682942,936674,928
Tina HuntRSU2025-02-136,5376,5371,349,949
Martin SmithRSU2025-02-131,4682942,936674,928
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Martin Smith$2,699,805$0$00.0%
Jonathan Mazelsky010,799,8820100.0%
Tina Hunt2,699,805000.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Jonathan MazelskyRSU9,276$6,275,492
Brian McKeonPSU928627,820
Brian McKeonRSU596403,212
Brian McKeonRSU303204,989
Tina HuntRSU204138,012
Martin SmithRSU903610,907
Michael LaneRSU903610,907
Martin SmithRSU1,468993,146
Michael LaneRSU1,468993,146
Andrew EmersonRSU188127,188
Michael LaneRSU204138,012
Tina HuntRSU903610,907
Tina HuntPSU1,204814,542
Andrew EmersonRSU12584,566
Andrew EmersonRSU1,033698,855
Tina HuntOption6,537459.76
Martin SmithPSU1,204814,542
Martin SmithOption6,537459.76
Andrew EmersonOption4,600459.76
Jonathan MazelskyOption10,728497.43
Martin SmithRSU376254,375
Michael LaneRSU440297,673
Martin SmithOption2,758497.43
Michael LaneOption3,218497.43
Andrew EmersonPSU167112,981
Andrew EmersonOption460497.43
Martin SmithRSU148100,126
Michael LanePSU2,9361,986,292
Tina HuntRSU1,468993,146
Tina HuntPSU2,9361,986,292
Martin SmithPSU2,9361,986,292
Michael LanePSU1,204814,542
Jonathan MazelskyRSU958648,116
Michael LaneOption6,537459.76
Jonathan MazelskyRSU23,49015,891,690
Jonathan MazelskyOption26,149459.76
Jonathan MazelskyRSU2,1981,487,013
Andrew EmersonPSU2,0661,397,711
Tina HuntRSU1,5081,020,207
Brian McKeonRSU615416,066
Tina HuntRSU414280,083
Brian McKeonOption4,506497.43
Tina HuntOption3,034497.43
05

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation philosophy is to attract, motivate, focus and retain talented executives who are aligned with, and passionate about, our Purpose: to be a great company that creates exceptional long-term value for our customers, employees and shareholders by enhancing the health and well-being of pets, people and livestock.

CEO STI target (% of salary)130%
CEO LTI target (% of salary)
Independent consultantFarient
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-1264,399,1563,954,02673,62994.22%Passed
20252025-05-0763,288,5964,375,655409,90593.53%Passed
20242024-05-0664,265,4434,412,055458,53993.58%Passed
20232023-05-1765,447,3483,468,812179,12194.97%Passed
20222022-05-1166,515,8433,643,026157,94594.81%Passed
20212021-05-1266,390,7973,860,320107,05094.5%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-1294.22%a
20252025-05-0793.53%b
20242024-05-0693.58%c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes (which are described below) are not counted as votes cast and so have no effect on the outcome of these proposals.”.

b. Approved under the standard stated in the filing — “Abstentions and broker non-votes (which are described below) are not counted as votes cast and so have no effect on the outcome of these proposals.”.

c. Approved under the standard stated in the filing — “Abstentions and broker non-votes (which are described below) are not counted as votes cast and so have no effect on the outcome of the proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)218 : 1
CEO total compensation$14,580,122
Median employee compensation$66,956
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Lawrence D. KingsleyIndependent · Board Chair · Lead Independent Director · Compensation and Talent · Governance and Corporate Responsibility$170,000$164,961$164,882$0$-1$499,842
M. Anne SzostakIndependent · Audit · Governance and Corporate Responsibility (Chair)122,500125,059124,9100372,469
Irene Chang BrittIndependent · Audit · Compensation and Talent (Chair)122,500125,059124,9100372,469
Daniel M. JuniusIndependent · Audit (Chair) · Finance120,000125,059124,9100369,969
Stuart M. Essig, PhDIndependent · Finance (Chair) · Governance and Corporate Responsibility105,000125,059124,9100354,969
Bruce L. ClaflinIndependent · Audit · Compensation and Talent97,500125,059124,9100347,469
Sam SamadIndependent · Audit · Compensation and Talent97,500125,059124,9100347,469
Sophie V. Vandebroek, PhDIndependent · Finance · Governance and Corporate Responsibility90,000125,059124,9100339,969
Joseph L. (Jay) HooleyIndependent · Audit · Governance and Corporate Responsibility · Newly elected46,366102,240102,49801251,105
Karen PeacockIndependent · Compensation and Talent · Finance · Newly elected21,27773,62673,1800168,083
Asha S. Collins, PhDIndependent · Departed during FY22,500022,500
Jonathan J. MazelskyEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$90,000
Annual equity retainer$250,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)30,000 / 25,000 / 25,000
Stock ownership guideline6x annual retainer
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$1,015,143
Equity awards (grant-date value)$1,216,240
All other compensation$0
Total cost of the board$2,231,383

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies IDEXX Laboratories names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including IDEXX Laboratories.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Intuitive Surgical, Inc.2025David Rosa$858,750$18,674,872$0$1,373,859$20,997,480
2Align Technology, Inc.2025Joseph Hogan1,400,00016,556,87201,220,10019,193,988
3Zoetis Inc.2025Kristin Peck1,350,00010,218,5833,406,2292,187,00019,046,509
4Edwards Lifesciences Corporation2025Bernard Zovighian1,192,5007,167,0246,499,1092,406,53717,454,255
5The Cooper Companies, Inc.2025Albert White III1,170,7696,642,9186,643,0501,525,95116,051,141
6Hologic, Inc.2024Stephen MacMillan1,212,6289,141,4682,937,4771,990,41315,819,261
7Elanco Animal Health Incorporated2025Jeffrey Simmons1,200,0009,000,0003,000,0041,700,40014,925,756
8ResMed Inc.2025Michael Farrell1,214,1508,775,0592,925,0071,646,74314,674,543
9IDEXX Laboratories2025Jonathan Mazelsky1,150,0005,399,8815,400,0012,593,00014,580,122
10Waters Corporation2025Udit Batra1,150,0007,430,2472,999,9222,371,87513,973,044
11Revvity, Inc.2025Prahlad R. Singh1,129,2317,694,9852,559,1522,385,45013,809,549
12Agilent Technologies, Inc.2025Padraig McDonnell1,141,3458,169,8502,017,7591,436,80912,827,236
13STERIS plc2026Daniel Carestio1,095,7074,333,9514,334,2511,725,00711,508,522
14Illumina, Inc.2025Jacob Thaysen1,000,0008,763,12201,155,00011,018,895
15Bio-Rad Laboratories, Inc.2025Norman Schwartz1,089,8774,856,5741,458,975562,0887,995,841
16DexCom, Inc.2025Jacob Leach768,9625,936,06201,164,7807,985,960
17Mettler-Toledo International Inc.2025Patrick Kaltenbach1,145,9993,267,8081,635,033462,9846,741,212

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
IDEXX Laboratories140%Options 50 · PSU 50NoFarient
Agilent Technologies, Inc.not disclosedPSU 60 · Options 20 · RSU 20NoSemler Brossy
Align Technology, Inc.58.1%MSU 70 · RSU 30Yes — Relative Total Stockholder Return (TSR) vs. Nasdaq Composite IndexCompensia, Inc.
Bio-Rad Laboratories, Inc.not disclosednot disclosednot disclosedCompensia, Inc.
DexCom, Inc.not disclosednot disclosedYes — Relative TSR Performance MetricAon Hewitt Consulting Company
Edwards Lifesciences Corporation127%Options 50 · PSU 25 · RSU 25NoSemler Brossy Consulting Group
Elanco Animal Health Incorporatednot disclosedPSU 50 · RSU 25 · Options 25NoWillis Towers Watson (WTW)
Hologic, Inc.109%PSU 50 · RSU 25 · Options 25Nonot disclosed
Illumina, Inc.1155%not disclosedYes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology IndexAon (Aon's Human Capital Practice, a division of Aon, plc)
Intuitive Surgical, Inc.115.2%RSU 50 · PSU 50NoAon
Mettler-Toledo International Inc.80%PSU 33 · RSU 33 · Options 33Yes — Relative Total Shareholder Return (rTSR)Pearl Meyer & Partners (PM&P)
ResMed Inc.102%PSU 50 · RSU 25 · Options 25Yes — Absolute TSRFW Cook, Inc.
Revvity, Inc.124%PSU 50 · RSU 25 · Options 25NoPearl Meyer
STERIS plc125.1%RSU 50 · Options 50not disclosedFrederic W. Cook & Co., Inc.
The Cooper Companies, Inc.100.9%Options 50 · PSU 50NoCompensia
Waters Corporation110%PSU 50 · Options 35 · RSU 15Yes — Relative Total Shareholder Return (rTSR)Pearl Meyer
Zoetis Inc.108%PSU 50 · Options 25 · RSU 25Yes — Relative TSRPearl Meyer

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Jonathan MazelskyDEF 14A2026-03-270000874716-26-000064Section “Summary Compensation Table for 2025”. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018
2Section 01, Michael LaneDEF 14A2026-03-270000874716-26-000064Section “Summary Compensation Table for 2025”. As printed: 4,019,416. Filing ↗machine: span 1592569–1592578
3Section 01, Tina HuntDEF 14A2026-03-270000874716-26-000064Section “Summary Compensation Table for 2025”. As printed: 3,945,293. Filing ↗machine: span 1604543–1604552
4Section 01, Martin SmithDEF 14A2026-03-270000874716-26-000064Section “Summary Compensation Table for 2025”. As printed: 3,944,534. Filing ↗machine: span 1616717–1616726
5Section 01, Andrew EmersonDEF 14A2026-03-270000874716-26-000064Section “Summary Compensation Table for 2025”. As printed: 3,033,071. Filing ↗machine: span 1588033–1588042
6Section 01, Brian McKeonDEF 14A2026-03-270000874716-26-000064Section “Summary Compensation Table for 2025”. As printed: 351,680. Filing ↗machine: span 1625140–1625147
7Section 03, Martin Smith RSUDEF 14A2026-03-270000874716-26-000064Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t228 · r17 · c18 · span 1716780–1716789
8Section 03, Martin Smith RSUDEF 14A2026-03-270000874716-26-000064Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t228 · r19 · c19 · span 1725982–1725989
9Section 03, Jonathan Mazelsky PSUDEF 14A2026-03-270000874716-26-000064Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t228 · r4 · c19 · span 1656587–1656596
10Section 03, Jonathan Mazelsky PSUDEF 14A2026-03-270000874716-26-000064Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t228 · r5 · c18 · span 1661114–1661123
11Section 03, Tina Hunt RSUDEF 14A2026-03-270000874716-26-000064Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t228 · r15 · c19 · span 1707619–1707626
12Section 03, Tina Hunt RSUDEF 14A2026-03-270000874716-26-000064Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t228 · r15 · c19 · span 1707619–1707626
13Section 03, Tina Hunt RSUDEF 14A2026-03-270000874716-26-000064Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t228 · r17 · c18 · span 1716780–1716789
14Section 03, Martin Smith RSUDEF 14A2026-03-270000874716-26-000064Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t228 · r15 · c19 · span 1707619–1707626
15Section 07, pay ratioDEF 14A2026-03-270000874716-26-000064Section “CEO Pay Ratio”. As printed: 218 : 1. Filing ↗machine: span 2135068–2135076
16Section 08, Lawrence D. KingsleyDEF 14A2026-03-270000874716-26-000064Section “Director Compensation”. As printed: 499,842. Filing ↗machine: t143 · r9 · c10 · span 977243–977250
17Section 08, M. Anne SzostakDEF 14A2026-03-270000874716-26-000064Section “Director Compensation”. As printed: 372,469. Filing ↗machine: t143 · r12 · c10 · span 985614–985621
18Section 08, Irene Chang BrittDEF 14A2026-03-270000874716-26-000064Section “Director Compensation”. As printed: 372,469. Filing ↗machine: t143 · r3 · c10 · span 960270–960277
19Section 08, Daniel M. JuniusDEF 14A2026-03-270000874716-26-000064Section “Director Compensation”. As printed: 369,969. Filing ↗machine: t143 · r8 · c10 · span 974513–974520
20Section 08, Stuart M. Essig, PhDDEF 14A2026-03-270000874716-26-000064Section “Director Compensation”. As printed: 354,969. Filing ↗machine: t143 · r6 · c10 · span 968598–968605
21Section 08, Bruce L. ClaflinDEF 14A2026-03-270000874716-26-000064Section “Director Compensation”. As printed: 347,469. Filing ↗machine: t143 · r4 · c10 · span 962936–962943
22Section 08, Sam SamadDEF 14A2026-03-270000874716-26-000064Section “Director Compensation”. As printed: 347,469. Filing ↗machine: t143 · r11 · c10 · span 982885–982892
23Section 08, Sophie V. Vandebroek, PhDDEF 14A2026-03-270000874716-26-000064Section “Director Compensation”. As printed: 339,969. Filing ↗machine: t143 · r13 · c10 · span 988691–988698
24Section 08, Joseph L. (Jay) HooleyDEF 14A2026-03-270000874716-26-000064Section “Director Compensation”. As printed: 251,105. Filing ↗machine: t143 · r7 · c10 · span 971784–971791
25Section 08, Karen PeacockDEF 14A2026-03-270000874716-26-000064Section “Director Compensation”. As printed: 168,083. Filing ↗machine: t143 · r10 · c10 · span 980165–980172
26Section 08, Asha S. Collins, PhDDEF 14A2026-03-270000874716-26-000064Section “Director Compensation”. As printed: 22,500. Filing ↗machine: t143 · r5 · c1 · span 963938–963944
27Section 08, Jonathan J. MazelskyDEF 14A2026-03-270000874716-26-000064Section “Director Compensation”. As printed: 0. Filing ↗
28Section 02, Joseph L. (Jay) Hooley 2026-04-30Form 42026-05-040000874716-26-000069Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Joseph L. (Jay) Hooley 2026-05-07Form 42026-05-110000874716-26-000083Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, M. Anne Szostak 2026-05-07Form 42026-05-110000874716-26-000087Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Karen Peacock 2026-05-07Form 42026-05-110000874716-26-000086Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Lawrence D. Kingsley 2026-05-07Form 42026-05-110000874716-26-000085Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, Daniel M. Junius 2026-05-07Form 42026-05-110000874716-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, Joseph L. (Jay) Hooley 2026-05-07Form 42026-05-110000874716-26-000083Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, Lawrence D. Kingsley 2026-05-07Form 42026-05-110000874716-26-000085Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, Sophie V. Vandebroek, PhD 2026-05-07Form 42026-05-110000874716-26-000088Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, Sophie V. Vandebroek, PhD 2026-05-07Form 42026-05-110000874716-26-000088Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, Karen Peacock 2026-05-07Form 42026-05-110000874716-26-000086Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, Lawrence D. Kingsley 2026-05-07Form 42026-05-110000874716-26-000085Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, Daniel M. Junius 2026-05-07Form 42026-05-110000874716-26-000084Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, Lawrence D. Kingsley 2026-05-07Form 42026-05-110000874716-26-000085Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, M. Anne Szostak 2026-05-07Form 42026-05-110000874716-26-000087Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, Stuart M. Essig, PhD 2026-05-12Form 42026-05-140000874716-26-000101Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, Joseph L. (Jay) Hooley 2026-05-12Form 42026-05-140000874716-26-000102Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, Stuart M. Essig, PhD 2026-05-12Form 42026-05-140000874716-26-000101Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, Bruce L. Claflin 2026-05-12Form 42026-05-140000874716-26-000100Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Sam Samad 2026-05-12Form 42026-05-140000874716-26-000106Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Sam Samad 2026-05-12Form 42026-05-140000874716-26-000106Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Sophie V. Vandebroek, PhD 2026-05-12Form 42026-05-140000874716-26-000107Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Sophie V. Vandebroek, PhD 2026-05-12Form 42026-05-140000874716-26-000107Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Karen Peacock 2026-05-12Form 42026-05-140000874716-26-000105Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Lawrence D. Kingsley 2026-05-12Form 42026-05-140000874716-26-000104Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Daniel M. Junius 2026-05-12Form 42026-05-140000874716-26-000103Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Karen Peacock 2026-05-12Form 42026-05-140000874716-26-000105Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Lawrence D. Kingsley 2026-05-12Form 42026-05-140000874716-26-000104Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Lawrence D. Kingsley 2026-05-12Form 42026-05-140000874716-26-000104Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Lawrence D. Kingsley 2026-05-12Form 42026-05-140000874716-26-000104Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Daniel M. Junius 2026-05-12Form 42026-05-140000874716-26-000103Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Bruce L. Claflin 2026-05-12Form 42026-05-140000874716-26-000100Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Irene Chang Britt 2026-05-12Form 42026-05-140000874716-26-000099Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Irene Chang Britt 2026-05-12Form 42026-05-140000874716-26-000099Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Joseph L. (Jay) Hooley 2026-05-12Form 42026-05-140000874716-26-000102Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, George Fennell 2026-06-01Form 42026-06-020000874716-26-000114Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, George Fennell 2026-06-01Form 42026-06-020000874716-26-000114Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, George Fennell 2026-06-01Form 42026-06-020000874716-26-000114Insider equity transaction reported since the proxy statement. Filing ↗
66Section 06, 2026 voteForm 8-K2026-05-150000874716-26-000110Item 5.07 · say-on-pay result. As reported: 94.22% (votes for as printed: 64,399,156). Filing ↗
67Section 06, 2025 voteForm 8-K2025-05-090000874716-25-000085Item 5.07 · say-on-pay result. As reported: 93.53% (votes for as printed: 63,288,596). Filing ↗
68Section 06, 2024 voteForm 8-K2024-05-100000874716-24-000107Item 5.07 · say-on-pay result. As reported: 93.58% (votes for as printed: 64,265,443). Filing ↗
69Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
70Section 09b board cost (computed)ComputedcomputedCash 1,015,143 + equity 1,216,240 + all other 0 = 2,231,383, summed across the director compensation table rows.machine: formula: Σ = 2,231,383
71Intuitive Surgical, Inc., Section 10b CEO totalDEF 14A2026-03-130001035267-26-000023CEO total compensation as printed in Intuitive Surgical, Inc.'s own proxy. As printed: 20,997,480. Filing ↗machine: r2 · c48 · span 762289–762299
72Align Technology, Inc., Section 10b CEO totalDEF 14A2026-04-070001097149-26-000023CEO total compensation as printed in Align Technology, Inc.'s own proxy. As printed: 19,193,988. Filing ↗machine: r2 · c42 · span 933168–933178
73Zoetis Inc., Section 10b CEO totalDEF 14A2026-04-080001555280-26-000015CEO total compensation as printed in Zoetis Inc.'s own proxy. As printed: 19,046,509. Filing ↗machine: r3 · c24 · span 1448788–1448798
74Edwards Lifesciences Corporation, Section 10b CEO totalDEF 14A2026-03-260001099800-26-000015CEO total compensation as printed in Edwards Lifesciences Corporation's own proxy. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451
75The Cooper Companies, Inc., Section 10b CEO totalDEF 14A2026-02-240001628280-26-011110CEO total compensation as printed in The Cooper Companies, Inc.'s own proxy. As printed: 16,051,141. Filing ↗machine: t120 · r3 · c14 · span 744904–744914
76Hologic, Inc., Section 10b CEO totalDEF 14A2025-01-160001140361-25-001287CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674
77Elanco Animal Health Incorporated, Section 10b CEO totalDEF 14A2026-04-080001739104-26-000016CEO total compensation as printed in Elanco Animal Health Incorporated's own proxy. As printed: 14,925,756. Filing ↗machine: r4 · c24 · span 1067844–1067854
78ResMed Inc., Section 10b CEO totalDEF 14A2025-10-020000943819-25-000079CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 14,674,543. Filing ↗machine: span 1328668–1328678
79IDEXX Laboratories (subject), Section 10b CEO totalDEF 14A2026-03-270000874716-26-000064CEO total compensation as printed in IDEXX Laboratories's own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018
80Waters Corporation, Section 10b CEO totalDEF 14A2026-04-090001193125-26-149657CEO total compensation as printed in Waters Corporation's own proxy. As printed: 13,973,044. Filing ↗machine: r5 · c18 · span 568522–568533
81Revvity, Inc., Section 10b CEO totalDEF 14A2026-03-160001193125-26-107266CEO total compensation as printed in Revvity, Inc.'s own proxy. As printed: 13,809,549. Filing ↗machine: span 751285–751295
82Agilent Technologies, Inc., Section 10b CEO totalDEF 14A2026-02-060001193125-26-040286CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992
83STERIS plc, Section 10b CEO totalDEF 14A2026-06-110001193125-26-267599CEO total compensation as printed in STERIS plc's own proxy. As printed: 11,508,522. Filing ↗machine: t172 · r6 · c34 · span 820590–820600
84Illumina, Inc., Section 10b CEO totalDEF 14A2026-04-090001193125-26-149669CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536
85Bio-Rad Laboratories, Inc., Section 10b CEO totalDEF 14A2026-03-250000012208-26-000020CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209
86DexCom, Inc., Section 10b CEO totalDEF 14A2026-04-150001093557-26-000061CEO total compensation as printed in DexCom, Inc.'s own proxy. As printed: 7,985,960. Filing ↗machine: span 940364–940373
87Mettler-Toledo International Inc., Section 10b CEO totalDEF 14A2026-03-180001174947-26-000389CEO total compensation as printed in Mettler-Toledo International Inc.'s own proxy. As printed: 6,741,212. Filing ↗machine: r2 · c7 · span 643529–643538
88Section 10a, Agilent Technologies, Inc. reciprocityDEF 14A0001193125-26-040286Agilent Technologies, Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
89Section 10a, ResMed Inc. reciprocityDEF 14A0000943819-25-000079ResMed Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
90Section 10a, STERIS plc reciprocityDEF 14A0001193125-26-267599STERIS plc names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
91Section 10a, Zoetis Inc. reciprocityDEF 14A0001555280-26-000015Zoetis Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
92Section 10a, Align Technology, Inc. reciprocityDEF 14A0001097149-26-000023Align Technology, Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
93Section 10a, The Cooper Companies, Inc. reciprocityDEF 14A0001628280-26-011110The Cooper Companies, Inc.'s most recent proxy was read; its disclosed peer group does not include IDEXX Laboratories. Filing ↗
94Section 10a, DexCom, Inc. reciprocityDEF 14A0001093557-26-000061DexCom, Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
95Section 10a, Edwards Lifesciences Corporation reciprocityDEF 14A0001099800-26-000015Edwards Lifesciences Corporation names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
96Section 10a, Waters Corporation reciprocityDEF 14A0001193125-26-149657Waters Corporation names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
97Section 10a, Hologic, Inc. reciprocityDEF 14A0001140361-25-001287Hologic, Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
98Section 10a, Elanco Animal Health Incorporated reciprocityDEF 14A0001739104-26-000016Elanco Animal Health Incorporated names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗
99Section 10a, Mettler-Toledo International Inc. reciprocityDEF 14A0001174947-26-000389Mettler-Toledo International Inc.'s most recent proxy was read; its disclosed peer group does not include IDEXX Laboratories. Filing ↗
100Section 10a, Revvity, Inc. reciprocityDEF 14A0001193125-26-107266Revvity, Inc.'s most recent proxy was read; its disclosed peer group does not include IDEXX Laboratories. Filing ↗
101Section 10a, Intuitive Surgical, Inc. reciprocityDEF 14A0001035267-26-000023Intuitive Surgical, Inc. names IDEXX Laboratories in its own disclosed peer group (read from its most recent proxy). Filing ↗